1-20 of 114 results for primarymember:"Lord Kakkar"
Librarians' tools
- Search time
- 0.304 seconds
- Solr query time
- 0.003 seconds
- Search query
- primarymember:"Lord Kakkar"
- We searched for
- primaryMember_ses:301549
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
Lords motion to agree the eleventh report of the Conduct Committee on The conduct of Lord Stone of Blackheath (HL 295 2024-26). Agreed to on question.
Lords motion to agree the eleventh report of the Conduct Committee on The conduct of Lord Stone of Blackheath (HL 295 2024-26). Agreed to on question.
Lords motion to agree the tenth report of the Conduct Committee on The conduct of Lord Chadlington (HL 272). Agreed to on question.
Lords motion to agree the tenth report of the Conduct Committee on The conduct of Lord Chadlington (HL 272). Agreed to on question.
My Lords, I declare my interest as chairman of King’s Health Partners. The Minister made reference to AI stethoscopes aiding in the diagnosis of patients with heart conditions. The evidence for this was established in a very large trial—the TRICORDER trial—involving some 1.5 million patients and more than 200 general practices in our country. What it demonstrated was, compared to the use of the ordinary standard of care, a doubling of the rate of diagnosis for heart failure and a tripling of the rate of diagnosis for heart arrhythmias. The problem was that, subsequent to the trial, the diagnostic rate did not increase, suggesting that it is necessary to invest in training and the establishment of new working pathways to ensure that innovation can be properly established in routine clinical practice. Is His Majesty’s Government funding such activity?
My Lords, I declare my interest as chairman of King’s Health Partners. The Minister made reference to AI stethoscopes aiding in the diagnosis of patients with heart conditions. The evidence for this was established in a very large trial—the TRICORDER trial—involving some 1.5 million patients and more than 200 general practices in our country. What it demonstrated was, compared to the use of the ordinary standard of care, a doubling of the rate of diagnosis for heart failure and a tripling of the rate of diagnosis for heart arrhythmias. The problem was that, subsequent to the trial, the diagnostic rate did not increase, suggesting that it is necessary to invest in training and the establishment of new working pathways to ensure that innovation can be properly established in routine clinical practice. Is His Majesty’s Government funding such activity?
The noble Lord is right to make the point that innovation research is one part of it, but it is actually its implementation that matters.
However, the faster and more frequent detection of cardiovascular conditions is the key thing and training is certainly a part of that.
Lords motion to approve the appointment of the Rt Hon Dame Anne Rafferty DBE as a House of Lords Commissioner for Standards for a period of five years; and extends the appointment of Martin Jelley QPM DL as a House of Lords Commissioner for Standards to 30 June 2029. Agreed to on question.
Lords motion to approve the appointment of the Rt Hon Dame Anne Rafferty DBE as a House of Lords Commissioner for Standards for a period of five years; and extends the appointment of Martin Jelley QPM DL as a House of Lords Commissioner for Standards to 30 June 2029. Agreed...
My Lords, much of the future improvement in productivity in the NHS is predicated on the adoption of innovative technologies. Is the Minister content that there is sufficient investment in the continuing development of the NHS workforce to facilitate the adoption of that technology and deliver that improvement in productivity?
My Lords, much of the future improvement in productivity in the NHS is predicated on the adoption of innovative technologies. Is the Minister content that there is sufficient investment in the continuing development of the NHS workforce to facilitate the adoption of that technology and deliver that improvement in productivity?
I am. We are investing £10 billion in digital technologies within the NHS. We have introduced a 2% efficiency and productivity target in the NHS for each year of this Parliament. That is supported by the Government’s 10-year health plan for England, which will improve outcomes for patients and deliver better value for money for taxpayers. The noble Lord is absolutely right that digital technologies and their adoption is vital to that. As I say, that is why we have invested £10 billion in it. We are moving more healthcare into the community and we are focusing more on the prevention of illnesses.
My Lords, I draw the House’s attention to my registered interest as chairman of King’s Health Partners. Is the Minister content that sufficient resources are applied to the molecular characterisation of screen-detected breast cancer in such a way that those over the age of 70 who have breast cancer detected are appropriately treated?
My Lords, I draw the House’s attention to my registered interest as chairman of King’s Health Partners. Is the Minister content that sufficient resources are applied to the molecular characterisation of screen-detected breast cancer in such a way that those over the age of 70 who have breast cancer detected are appropriately treated?
I should be able to answer, I admit, but I would rather be honest with the noble Lord: I would prefer to write to him because of the specific nature of his question. I am content with the role of the research trial and that we are now harnessing AI tools through the EDITH trial backed by some £11 million of government support. Using cross-cutting AI tools in respect of the breast cancer screening pathway will be of great assistance.
Lords motion to agree the eighth report of the Conduct Committee on The conduct of Lord Evans of Watford (HL 220). Agreed to on question. Lords motion to resolve that, in accordance with Standing Order 11, Lord Evans of Watford be suspended from the service of the House for a period of five months; and that, in accordance with section 1 of the House of Lords (Expulsion and Suspension) Act 2015, in the opinion of this House, the conduct giving rise to this resolution occurred after the coming into force of that Act. Agreed to on question.
Lords motion to agree the eighth report of the Conduct Committee on The conduct of Lord Evans of Watford (HL 220). Agreed to on question. Lords motion to resolve that, in accordance with Standing Order 11, Lord Evans of Watford be suspended from the service of the House for a...
Lords motion to agree the seventh report of the Conduct Committee on The conduct of Lord Dannatt (HL 219). Agreed to on question. Lords motion to resolve that, in accordance with Standing Order 11, Lord Dannatt be suspended from the service of the House for a period of four months; and that, in accordance with section 1 of the House of Lords (Expulsion and Suspension) Act 2015, in the opinion of this House, the conduct giving rise to this resolution occurred after the coming into force of that Act. Agreed to on question.
Lords motion to agree the seventh report of the Conduct Committee on The conduct of Lord Dannatt (HL 219). Agreed to on question. Lords motion to resolve that, in accordance with Standing Order 11, Lord Dannatt be suspended from the service of the House for a period of four months;...
Lords motion to agree the sixth report of the Conduct Committee on The conduct of Baroness D'Souza (HL 184). Agreed to on question. Lords motion to resolve that, in accordance with Standing Order 11, Baroness D'Souza be suspended from the service of the House for a period of eight weeks; and that, in accordance with section 1 of the House of Lords (Expulsion and Suspension) Act 2015, in the opinion of this House, the conduct giving rise to this resolution occurred after the coming into force of that Act. Agreed to on question.
Lords motion to agree the sixth report of the Conduct Committee on The conduct of Baroness D'Souza (HL 184). Agreed to on question. Lords motion to resolve that, in accordance with Standing Order 11, Baroness D'Souza be suspended from the service of the House for a period of eight weeks;...
My Lords, I draw attention to my interest as chairman of UK Biobank. The value of large-cohort studies is not only in the collection of baseline data, and indeed, in this case, the genome sequences of the 100,000 newborns, but in the opportunity to secure the long-term longitudinal follow-up of participants, so that there is a broader understanding of the change in health and health dynamics.
The Minister mentioned the question of consent with regard to genetic testing, but there is another question of consent, with regard to long-term access to the primary care data of those individuals who have participated in the study. Is the Minister content that there are appropriate arrangements in place with regard to consent to ensure long-term access to primary care data for those individuals?
My Lords, I draw attention to my interest as chairman of UK Biobank. The value of large-cohort studies is not only in the collection of baseline data, and indeed, in this case, the genome sequences of the 100,000 newborns, but in the opportunity to secure the long-term longitudinal follow-up of participants, so that there is a broader understanding of the change in health and health dynamics.
The Minister mentioned the question of consent with regard to genetic testing, but there is another question of consent, with regard to long-term access to the primary care data of those individuals who have participated in the study. Is the Minister content that there are appropriate arrangements in place with regard to consent to ensure long-term access to primary care data for those individuals?
The noble Lord raises a very good point. Certainly, it is part of how we develop the use of data. I am aware that he did not directly ask me this, but perhaps I might use the opportunity to say that data safety, which I know is a matter of concern to many noble Lords, is absolutely paramount here. We also have absolute regard to conducting studies ethically, but the point about primary care data, its use and its value, as well as its safety, is very well made and one which we are certainly developing still further.
I draw the House’s attention to my registered interest as chairman of King’s Health Partners. The 10-year plan recently published by His Majesty’s Government, with regard to the future of the NHS, puts at its very centre the adoption of innovation at scale and pace to transform the health service and secure its sustainability. What arrangements are in place, and what assessment is being made of those mechanisms? In particular, do His Majesty’s Government have a view about advancing the opportunity
for early adoption of innovation in such a way that the kinds of problems we have heard about in this short Question are not repeated on several occasions, and the ambition to transform the health service with innovation is not frustrated?
I draw the House’s attention to my registered interest as chairman of King’s Health Partners. The 10-year plan recently published by His Majesty’s Government, with regard to the future of the NHS, puts at its very centre the adoption of innovation at scale and pace to transform the health service and secure its sustainability. What arrangements are in place, and what assessment is being made of those mechanisms? In particular, do His Majesty’s Government have a view about advancing the opportunity
for early adoption of innovation in such a way that the kinds of problems we have heard about in this short Question are not repeated on several occasions, and the ambition to transform the health service with innovation is not frustrated?
The noble Lord raises a crucial point: there is no point having all the work going into innovation if we cannot implement it. It is at the centre of the 10-year plan. A process is being worked up to look at how we can bring the best of our innovation and technological advancement into clinical practice. I am grateful for his input into this area, and I know that this will be taken very seriously as we move forward.
My Lords, I draw noble Lords’ attention to my registered interest as chairman of King’s Health Partners. At the time when the decision was taken for NHS England to be fully incorporated into the Department of Health and Social Care, two other important agencies were completing their incorporation into NHS England—namely, NHS Digital and Health Education England. The functions of those two agencies in marshalling NHS data and its analysis and in providing for the continuing development of the NHS workforce are critical. Is the Minister able to confirm how those important functions are being protected during this period of transition of NHS England into the department?
My Lords, I draw noble Lords’ attention to my registered interest as chairman of King’s Health Partners. At the time when the decision was taken for NHS England to be fully incorporated into the Department of Health and Social Care, two other important agencies were completing their incorporation into NHS England—namely, NHS Digital and Health Education England. The functions of those two agencies in marshalling NHS data and its analysis and in providing for the continuing development of the NHS workforce are critical. Is the Minister able to confirm how those important functions are being protected during this period of transition of NHS England into the department?
The noble Lord, as always, raises exceptionally important points. The three shifts under the 10-year plan, particularly around moving from analogue to digital, answer the question on the need to focus on digital. These are ongoing discussions and, while the workforce will come down, it is critical that work is allowed to be done to assess what needs to be done and how we can move the health service, and therefore health outcomes, forward in the most productive and successful manner.
My Lords, I draw noble Lords’ attention to my interest as chairman of King’s Health Partners. Just to build on the point made by the right reverend Prelate, what assessment have His Majesty’s Government made of the impact on population health outcomes of the intersection between limited access to primary care services and diminishing availability of pharmacy services?
My Lords, I draw noble Lords’ attention to my interest as chairman of King’s Health Partners. Just to build on the point made by the right reverend Prelate, what assessment have His Majesty’s Government made of the impact on population health outcomes of the intersection between limited access to primary care services and diminishing availability of pharmacy services?
I know the noble Lord talked about primary care more generally, but the assessment on pharmacies is that there is quite a good coverage. Some 80% of the population live within a
mile of a pharmacy and, as I say, there are other online and not-in-person ways of contacting pharmacies. The Pharmacy Access Scheme provides financial support to pharmacies in areas where there are fewer pharmacies. Local authorities, along with ICBs, continue to monitor changes, look at provision and have the ability to intervene where necessary. On all these counts, in respect of primary care provided through pharmacy, which is so important, we continue to monitor the impact across ICBs. With regard to a particular assessment, I will gladly write with more details to the noble Lord.
My Lords, I draw noble Lords’ attention to my registered interests. The Minister will, I am sure, agree that, beyond physical infrastructure, one of the most important impediments to ensuring that there is effective integrated care between secondary and primary care settings is the question of regulation—professional and institutional regulation—which is quite different across those institutional boundaries. What plans do His Majesty’s Government have to look at the question of regulation to improve integrated care as part of their broader review of the delivery of healthcare in our country?
My Lords, I draw noble Lords’ attention to my registered interests. The Minister will, I am sure, agree that, beyond physical infrastructure, one of the most important impediments to ensuring that there is effective integrated care between secondary and primary care settings is the question of regulation—professional and institutional regulation—which is quite different across those institutional boundaries. What plans do His Majesty’s Government have to look at the question of regulation to improve integrated care as part of their broader review of the delivery of healthcare in our country?
The noble Lord is right to highlight regulation. Of course, there are many other aspects beyond physical infrastructure: for example, the use of technology, which also supports the subject on which we are speaking. All these matters are being considered as part of the 10-year plan and I am sure we all look forward to that reporting.
My Lords, I draw the House’s attention to my registered interests. Patients who are managed in research-active environments frequently have better clinical outcomes. For an environment, be it in the community or in the hospital, to be research active, it must be able to collect patient data; electronic records are therefore essential. Beyond that, there is a necessity to curate those data and present them in such a fashion that they can be used meaningfully and rapidly to drive our nation’s research effort and benefit all citizens. What plans do His Majesty’s Government have, as they move forward with the 10-year plan, to ensure that that area of development is properly funded?
My Lords, I draw the House’s attention to my registered interests. Patients who are managed in research-active environments frequently have better clinical outcomes. For an environment, be it in the community or in the hospital, to be research active, it must be able to collect patient data; electronic records are therefore essential. Beyond that, there is a necessity to curate those data and present them in such a fashion that they can be used meaningfully and rapidly to drive our nation’s research effort and benefit all citizens. What plans do His Majesty’s Government have, as they move forward with the 10-year plan, to ensure that that area of development is properly funded?
Research and data are absolutely key to the 10-year plan and the shifts that I referred to earlier. I also draw the noble Lord’s attention to the data security and protection toolkit. It is an online assessment tool that allows organisations to measure their performance against the National Data Guardian’s 10 data security standards. I know there is a question among some members of the public about this, but perhaps I could, overall, reassure the noble Lord that we see data as key to research. I certainly agree with his comments about outcomes for patients being better.
My Lords, I draw noble Lords’ attention to my registered interests. The funding base to support science in some of our leading universities, including those that may host these centres in the future, has become dependent on cross-subsidy from overseas student income. Is the Minister content that, with the obligation for universities to play a greater role in supporting those centres that receive MRC status, the funding base for scientific research in our universities is sufficiently secure to make that possible?
My Lords, I draw noble Lords’ attention to my registered interests. The funding base to support science in some of our leading universities, including those that may host these centres in the future, has become dependent on cross-subsidy from overseas student income. Is the Minister content that, with the obligation for universities to play a greater role in supporting those centres that receive MRC status, the funding base for scientific research in our universities is sufficiently secure to make that possible?
Universities have been under pressure, as the noble Lord knows, for a number of reasons, including student fees, overseas student numbers and questions about the full economic costs of research in addition to inflation. These are all important areas that will need to be looked at. It is worth remembering that, over the years, roughly one MRC unit per year has closed and a new one has started. This process is part of that continuing change, which I believe is important to make sure that we stay at the cutting edge. As part of that, the staff on the new wards will be fully paid. The principal investigator
salary is the one that will have to be picked up in part by a host institution or by other grants coming in to provide support.
My Lords, I draw attention to my registered interests. The Minister will be aware that the regulatory approaches to approving innovative medicines and to approving novel medical devices are quite different. With the introduction of AI to drive many of those devices, their impact on human health may be just as profound as administering a novel therapeutic. How do His Majesty’s Government propose to go about aligning the regulation of devices in the future when they are AI labelled?
My Lords, I draw attention to my registered interests. The Minister will be aware that the regulatory approaches to approving innovative medicines and to approving novel medical devices are quite different. With the introduction of AI to drive many of those devices, their impact on human health may be just as profound as administering a novel therapeutic. How do His Majesty’s Government propose to go about aligning the regulation of devices in the future when they are AI labelled?
We are taking a sector-specific approach to AI regulation. On medicines, we announced last week the formation of the regulatory innovation office, which will look specifically at the question of AI in healthcare to try to bring together the different regulators and make sure that we have a clear system.
I draw noble Lords’ attention to my registered interests. The Minister has identified the importance of having a framework for the adoption and standard incorporation of innovative technologies into routine care. In this regard, the long-term plan for the NHS that His Majesty’s Government are preparing is a vital element of what will happen over the next five years. Can the Minister confirm that that plan will look specifically at commissioning these innovations in such a way that life sciences innovation in our country is protected, and they get to patients quickly?
I draw noble Lords’ attention to my registered interests. The Minister has identified the importance of having a framework for the adoption and standard incorporation of innovative technologies into routine care. In this regard, the long-term plan for the NHS that His Majesty’s Government are preparing is a vital element of what will happen over the next five years. Can the Minister confirm that that plan will look specifically at commissioning these innovations in such a way that life sciences innovation in our country is protected, and they get to patients quickly?
Yes, I can confirm that we will be drawing on the parts of the report of the noble Lord, Lord Darzi, that refer to that. He refers to the need for innovation, to expand the use we make of life sciences and to develop that still further. That will very much form part of not just our thinking, but our doing.
My Lords, I draw noble Lords’ attention to my registered interests. The Minister indicated that we have got off to a good start in 2024, but that is particularly in terms of applications for European Research Council funding. The start has been less promising for Horizon pillar 2 funding, which requires collaboration between businesses and academia. What action do His Majesty’s Government propose to take to ensure that those kinds of relationships can once again be established and that we have a more successful approach to achieving that funding?
My Lords, I draw noble Lords’ attention to my registered interests. The Minister indicated that we have got off to a good start in 2024, but that is particularly in terms of applications for European Research Council funding. The start has been less promising for Horizon pillar 2 funding, which requires collaboration between businesses and academia. What action do His Majesty’s Government propose to take to ensure that those kinds of relationships can once again be established and that we have a more successful approach to achieving that funding?
The noble Lord is quite right that the numbers are looking more promising for 2024, particularly in the European Research Council mono-beneficiary schemes. In the collaborative and industry schemes, things still look fairly flat, although there are some examples of very good progress. In the European rail project, 61% in the most recent round had a UK participant and five out of the seven successful bids had UK participants, so there is some progress. We are doing a number of things: there is an increased communications campaign, the last one having led to a substantial increase of 64,000 hits on the UK Horizon website; there are roadshows, most recently in Birmingham and Glasgow and soon in Northern Ireland and Wales; there are pump priming grants, which have led to an ability to get money to work out how to make applications to Horizon programmes—I am pleased to say that of those people who received those grants and put in applications, 100% were eligible. Finally, European network programmes are being set up to link UK academic teams and industry to European teams in the most successful countries.
My Lords, I draw noble Lords’ attention to my registered interests. Research, development and production of vaccines will increasingly represent an important part of our national security strategy. Is the Minister content that there is sufficient investment in those three elements to ensure that we can secure our biosecurity in the future?
My Lords, I draw noble Lords’ attention to my registered interests. Research, development and production of vaccines will increasingly represent an important part of our national security strategy. Is the Minister content that there is sufficient investment in those three elements to ensure that we can secure our biosecurity in the future?
The noble Lord is absolutely right to raise this. As I said in the previous answer that I gave to my noble friend, the Government are investing significantly in the manufacturing capacity and the supply chain within the United Kingdom. In the event of an emergency, we have a supply chain within the United Kingdom so that we can supply the vaccines needed for its population.